- Home
- ANVS vs ATRA Comparison
ANVS vs ATRA Comparison
Compare ANVS & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- ATRA
- Stock Information
- Founded
- ANVS 2008
- ATRA 2012
- Country
- ANVS United States
- ATRA United States
- Employees
- ANVS N/A
- ATRA 89
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ANVS Health Care
- ATRA Health Care
- Exchange
- ANVS Nasdaq
- ATRA Nasdaq
- Market Cap
- ANVS 44.6M
- ATRA 51.1M
- IPO Year
- ANVS 2020
- ATRA 2014
- Fundamental
- Price
- ANVS $2.75
- ATRA $9.23
- Analyst Decision
- ANVS Strong Buy
- ATRA Buy
- Analyst Count
- ANVS 4
- ATRA 5
- Target Price
- ANVS $18.00
- ATRA $17.75
- AVG Volume (30 Days)
- ANVS 437.3K
- ATRA 34.5K
- Earning Date
- ANVS 08-14-2025
- ATRA 08-11-2025
- Dividend Yield
- ANVS N/A
- ATRA N/A
- EPS Growth
- ANVS N/A
- ATRA N/A
- EPS
- ANVS N/A
- ATRA N/A
- Revenue
- ANVS N/A
- ATRA $199,732,000.00
- Revenue This Year
- ANVS N/A
- ATRA N/A
- Revenue Next Year
- ANVS N/A
- ATRA N/A
- P/E Ratio
- ANVS N/A
- ATRA N/A
- Revenue Growth
- ANVS N/A
- ATRA 475.53
- 52 Week Low
- ANVS $1.11
- ATRA $5.01
- 52 Week High
- ANVS $14.80
- ATRA $18.71
- Technical
- Relative Strength Index (RSI)
- ANVS 57.81
- ATRA 64.09
- Support Level
- ANVS $2.24
- ATRA $7.54
- Resistance Level
- ANVS $2.97
- ATRA $8.25
- Average True Range (ATR)
- ANVS 0.26
- ATRA 0.47
- MACD
- ANVS 0.02
- ATRA 0.12
- Stochastic Oscillator
- ANVS 65.58
- ATRA 81.93
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).